

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of InnoCare Pharma Limited (the “**Company**”) dated 14 July 2023 in relation to, among others, resignation of independent non-executive director of the Company. The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces Dr. Dandan Dong (董丹丹) (“**Dr. Dong**”) has been appointed as an independent non-executive Director with effect from 11 October, 2023. Dr. Dong is primarily responsible for supervising and providing independent judgement to the Board.

The biographical details of Dr. Dong are set out below:

Dr. Dong, aged 39, currently serves as the chief business officer of ArriVent Biopharma, Inc. Prior to joining ArriVent Biopharma, Inc., Dr. Dong worked at Vivo Capital LLC from August 2011 to July 2021, and has held various positions there, including the managing director of Vivo Capital LLC and a managing member of the general partner of Vivo PANDA Fund and Vivo Innovation Fund II, Vivo Capital’s early-stage investment vehicles. Since November 2018, Dr. Dong has been serving as a director of VISEN Pharmaceuticals which as of the date of this announcement is in the course of seeking listing of its shares on the Main Board of the Stock Exchange of Hong Kong Limited. Dr. Dong obtained her Bachelor’s degree in life science from Sichuan University in July 2006. She completed the Pre-doctoral Fellowship program in infectious disease at New York University in July 2008, and obtained her Ph.D. degree in molecular microbiology from Fudan University in July 2011.

Dr. Dong has entered into a service contract with the Company for a term of three years from 11 October, 2023, subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company. In line with the remuneration policy and the recommendation of the remuneration committee of the Company (the “**Remuneration Committee**”), Dr. Dong will receive a monthly director’s service fee of RMB30,000 upon the effective date of her appointment. Under the terms of the service contract, she is entitled to bonus of such amount as the Board may determine in light of the Company’s business performance and the Director’s individual performance after confirmation by the Remuneration Committee.

Save as disclosed above and as at the date of this announcement, Dr. Dong (i) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationships with any directors, senior management or substantial shareholders of the Company; (iv) has not held in the last three years any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (v) meets the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Save as disclosed above, Dr. Dong confirms that, in relation to her appointment as the independent non-executive Director, there is no other information which is discloseable under Rule 13.51(2) of the Listing Rules, and the Company is not aware of any other matters in relation to the appointment that need to be brought to the attention of shareholders of the Company.

Upon the appointment of Dr. Dong as an independent non-executive Director, the Company is in compliance with the requirements under Rules 3.11 of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Dong in joining the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and executive Director

Hong Kong, 11 October 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu, Dr. Kaixian Chen and Dr. Dandan Dong as independent non-executive Directors.